SCHEMBL5437399

SCHEMBL5437399

Cc1cc(C(=O)N2CCC3(CC2)CCN(Cc2ccccc2OCC(C)C)C3OC(=O)C(F)(F)F)c(C)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR8 P51685 3/20 0.44
KCNH2 Q12809 3/20 0.44
MAPT P10636 3/20 0.42
ALDH1A1 P00352 5/20 0.40
HTT P42858 2/20 0.40
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 2/20 0.37
HSD17B10 Q99714 1/20 0.37
TSHR P16473 4/20 0.36
USP2 O75604 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPK1 P28482 1/20 0.35
PKM P14618 1/20 0.35
CYP2D6 P10635 1/20 0.34
CYP3A4 P08684 1/20 0.34
HIF1A Q16665 1/20 0.34
LMNA P02545 1/20 0.34
ACACB O00763 1/20 0.34
ACACA Q13085 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5428860 0.89 CCR8 (0.45) CCR8KCNH2ALDH1A1HTTMEN1
SCHEMBL5434095 0.87 CCR8 (0.46) CCR8KCNH2ALDH1A1TSHRUSP2
SCHEMBL5434109 0.87 CCR8 (0.46) CCR8KCNH2MAPTALDH1A1HTT
SCHEMBL5431626 0.86 CCR8 (0.46) CCR8KCNH2MAPTALDH1A1HTT
SCHEMBL5437628 0.86 CCR8 (0.47) CCR8KCNH2ALDH1A1TSHRUSP2
SCHEMBL5434137 0.86 CCR8 (0.46) CCR8KCNH2ALDH1A1TSHRUSP2
SCHEMBL5436595 0.86 CCR8 (0.45) CCR8KCNH2ALDH1A1TSHRUSP2
SCHEMBL5436908 0.85 CCR8 (0.53) CCR8KCNH2ALDH1A1TSHRUSP2
SCHEMBL5437621 0.85 CCR8 (0.44) CCR8KCNH2MAPTALDH1A1TSHR
SCHEMBL5431101 0.85 CCR8 (0.46) CCR8KCNH2ALDH1A1HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases ASTRAZENECA AB (SE) 2007-10-25 US disclosed
EP-1678178-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2006-07-12 EP disclosed
WO-2005040167-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases CCR8, CCR1, CCR10 CCR8 1/4885KCNH2 2793/4885MAPT 4197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.